Perrigo acquires GSK products as Mylan hovers
This article was originally published in Scrip
Irish-headquartered Perrigo, the subject of a recent unwilling takeover offer from Mylan, is to buy a portfolio of over-the-counter (OTC) brands from GlaxoSmithKline's Consumer Healthcare business. The deal is in connection with commitments that GSK made to the EC and other regulators ahead of the formation of the consumer health joint venture between GSK and Novartis, part of the mega asset swap deal that closed in February this year.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.